NCT03696121View on ClinicalTrials.gov

Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Stroke, Acute
Interventions
DRUG

Desmopressin Injection

Single dose 20 micrograms in 50ml Normal Saline as intravenous injection infused over 20 minutes

DRUG

Normal saline

Single dose 50ml Normal Saline as intravenous injection infused over 20 minutes

Trial Locations (1)

NG5 1PB

Nottingham City Hospital, Nottingham

All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

University of Nottingham

OTHER

NCT03696121 - Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage | Biotech Hunter | Biotech Hunter